Company news

Syntara Limited news in 2025

Syntara Limited's news releases, calls and decks from 2025, newest first.

View company

Skin scarring program to progress on positive Phase1a result

November 25, 2025

Quarterly Shareholder Report and Appendix 4C

October 27, 2025

Positive top-line Phase 2a data confirms competitive profile

September 29, 2025

Preliminary Final Report

August 28, 2025

Guidance from FDA on amsulostat clinical progression

August 11, 2025

Reinstatement to Quotation

August 4, 2025

Suspension from Quotation

July 31, 2025

Quarterly Appendix 4C Cash Flow Report

July 31, 2025

Quarterly Shareholder Report

July 30, 2025

New positive interim data in Phase 2 study of SNT-5505

June 12, 2025

SNT-5505 awarded US FDA Fast Track designation

June 9, 2025

Quarterly Activities Report

April 29, 2025

Acceleration of skin scarring program

March 17, 2025

Decks in 2025